Bliss GVS Pharma Q2 FY27 Results: Key Metrics to Watch

Bliss GVS Pharma Ltd will hold a board meeting on October 29, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company disclosed the meeting intimation on October 22. The update places investor attention on the company’s second-quarter performance after a stronger revenue showing in the June 2026 quarter. The results are for the second quarter of FY27, also referred to in some updates as Q2 2027. The board is expected to consider both standalone and consolidated numbers. The trading window has been closed from October 1, according to the announcement.

Board meeting is scheduled for October 29

The October 29 meeting is the confirmed upcoming earnings date for Bliss GVS Pharma. The agenda is limited to considering and approving unaudited financial results for the September quarter and the first half of FY27. No September-quarter revenue, profit, margin or earnings-per-share figure has been disclosed in the supplied information before the meeting. As a result, the company’s official filing will be the key source for evaluating the quarter. Investors will also be able to compare the September result with the June 2026 quarter and the September 2025 quarter. The half-year statement should provide the combined performance for the April-to-September period. The release will include separate standalone and consolidated disclosures.

June quarter set a higher revenue base

In the quarter ended June 30, 2026, Bliss GVS Pharma reported consolidated revenue from operations of ₹285.58 crore. That represented growth of 11.12% from ₹256.99 crore in the March 2026 quarter. Revenue was also 37.65% higher than ₹207.47 crore reported in the June 2025 quarter. Other income was ₹9.60 crore, taking total income to ₹295.18 crore. The reported revenue figure is commonly rounded to ₹286 crore in results summaries. The June quarter therefore provides the immediate operating benchmark for the September-quarter release.

Profit rose, while the reported net margin narrowed

Profit and loss for the June 2026 quarter was ₹51.37 crore, compared with ₹44.36 crore a year earlier. Other summaries place June-quarter net profit at about ₹51.0 crore, reflecting rounding and presentation differences. Earnings per share were reported at ₹4.73, up from ₹4.08 in the corresponding quarter of the prior year. A separate earnings summary put the net income increase at 16% year on year. It also reported a profit margin of 18%, compared with 21% in the prior-year quarter. Higher expenses were cited as the reason for the lower reported margin despite revenue and profit growth.

Operating profit improved sharply in June

The detailed quarterly data show total expenses of ₹209.18 crore in June 2026, compared with ₹166.14 crore in June 2025. Operating profit rose to ₹76.40 crore from ₹41.33 crore over the same period. EBITDA was ₹86.00 crore, versus ₹76.78 crore in the prior-year quarter. EBIT stood at ₹76.06 crore, while interest expense was ₹0.58 crore. Profit before tax was ₹75.48 crore and tax expense was ₹24.11 crore. These figures indicate that operating profit increased even as the cost base expanded. The September release will show whether this operating performance was sustained through the second quarter.

Key financial figures

FY26 offers broader context

For the year ended March 2026, Bliss GVS Pharma reported consolidated revenue of ₹927 crore, up 14% year on year. Consolidated net profit was ₹134.7 crore, also described as about ₹135 crore in rounded results reporting. Another full-year summary reported net income of ₹129 crore and earnings per share of ₹12.23, compared with ₹8.02 in FY25. That summary also put the full-year profit margin at 13%, up from 10% in FY25. The differences in stated annual profit reflect the source information provided and should be read alongside the company’s official consolidated filing. The reported FY26 revenue base remains the clearest measure of the company’s scale entering FY27.

Export concentration remains relevant

Exports accounted for about 91% of Bliss GVS Pharma’s FY26 sales, based on the available information. Sub-Saharan Africa accounted for about 80% of sales. This makes geographic sales mix an important context for evaluating quarterly performance. The September results may provide updated disclosures on revenue segments or export markets if the company includes them in its filing. No new export-market guidance or operational change has been stated in the board-meeting intimation. The available announcement is focused on the approval of financial results. Investors will therefore need to rely on the results release for any updated operating commentary.

What the market will assess after the release

The company’s June-quarter revenue growth created a relatively high comparison point for the September quarter. Market participants are likely to assess revenue progression against ₹285.58 crore in June and ₹244.40 crore in September 2025. They will also compare profitability with the ₹28.59 crore profit reported in the September 2025 quarter. Operating profit margin was 27% in June 2026, based on the detailed quarterly table, compared with 18% in September 2025. Any comparison should distinguish between operating margin and the separately reported net profit margin. The supplied information does not include a share-price move or a consensus estimate, so no market-price conclusion can be drawn before the results.

Why the September result matters

The September filing will complete the first-half view of FY27 and indicate whether the June-quarter growth trend continued. It will also provide a fresh reading on expenses, operating profit and net profitability. Revenue performance is particularly relevant given the company’s export-led sales profile. The release may help reconcile rounded figures used in earnings summaries with the detailed financial statement figures. It will also enable direct comparison with the September 2025 quarter, when consolidated revenue from operations was ₹244 crore and consolidated net profit was ₹27.25 crore. Bliss GVS Pharma’s board meeting on October 29 is the next confirmed event for these disclosures. The official unaudited standalone and consolidated results will determine the financial assessment for the quarter and first half ended September 30, 2026.